Our core business is the study of pharmacokinetics in the human brain at early preclinical stages using accurate predictive models and recent tools developed from human brain tissues. These tools include a proprietary blood-brain barrier model and fresh human brain slices that preserve physiological functions. We also have a physiologically-based pharmacokinetic model called Brain Exposure Prediction that provides in vivo time-curves of drug concentration in the brain based on in vitro generated pharmacokinetic parameters. BrainPlotting supports preclinical development plans and screening through these models and tools.